On the stock market since 2019, it operates in the world of health and science. It has 170 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
Average growth of 146% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
The cash pile is strong; debt and other items pull the grade toward the middle.
Clearly below the class average.
Sales are growing strongly for its sector.
The price is looking for direction — no strong breakout, no collapse.
Business Quality: Profit power and business quality trail similar companies in the sector.
Valuation: The stock trades at a price that looks expensive next to its earnings; that can cap future returns.
The stock trades 18% below its peak. The market has trimmed its expectations for the company.
Over the last 3 years, sales grew about 146% a year on average.
Sales run at $184.4M a year. A small number, but proof the product has real buyers.
There is $284.7M in the vault; even if every debt were paid off, $281.7M would remain.
A loss of $6.9M against $184.4M in annual sales.
Measured against its sector, the quality of the business sits below the class average. Report-card grade: 19/100.
Today’s price already includes part of tomorrow’s optimism. Report-card grade: 38/100.
On our five-subject report card, STOK sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: STOK is a high-risk stock — not yet profitable, and its future rides on its product catching on.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (38/100) says the stock isn’t cheap.